MicoRNA-214-3p: a key player in CPLX2-mediated inhibition on temozolomide resistance in glioma

Qian Peng1, Lijiao Wang2, Shuling Wang3

  • 1Medical Department Hunan Provincial People's Hospital, (the First Affiliated Hospital of Hunan Normal University), Changsha P.R. China.

Neurological Research
|September 19, 2022
PubMed
Abstract

Insights

Downregulating miR-214-3p inhibits temozolomide resistance in glioma by increasing CPLX2 expression. This finding offers a potential therapeutic strategy for overcoming drug resistance in brain tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
  • Temozolomide (TMZ) is a standard chemotherapeutic agent for GBM, but resistance often develops.
  • MicroRNAs (miRNAs) play crucial roles in cancer progression and drug resistance.

Purpose of the Study:

  • To investigate the role of miR-214-3p in regulating temozolomide (TMZ) resistance in glioma.
  • To determine if miR-214-3p targets CPLX2 (C জটিল প্রোটিন 2) and influences TMZ resistance.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) and Western blotting were used to assess miR-214-3p and CPLX2 expression in glioma tissues and cells.
  • TMZ-resistant glioma cell lines (U87/TMZ and U251/TMZ) were established and transfected with miR-214-3p mimic, inhibitor, or CPLX2 constructs.
  • Cell proliferation, apoptosis, and TMZ sensitivity (IC50) were evaluated.
  • Dual-luciferase reporter assays confirmed the binding relationship between miR-214-3p and CPLX2.

Main Results:

  • miR-214-3p was upregulated, and CPLX2 was downregulated in TMZ-resistant glioma tissues and cells compared to sensitive ones.
  • Overexpression of miR-214-3p increased proliferation and TMZ resistance while decreasing apoptosis in resistant cells.
  • Inhibition of miR-214-3p or overexpression of CPLX2 reduced proliferation and TMZ resistance and enhanced apoptosis.
  • CPLX2 was confirmed as a direct target of miR-214-3p.

Conclusions:

  • miR-214-3p promotes TMZ resistance in glioma by downregulating CPLX2.
  • Downregulation of miR-214-3p or upregulation of CPLX2 could be a therapeutic strategy to overcome TMZ resistance in glioma.